Full-Time

Key Account Manager

Biotech Pharma

Zeiss

Zeiss

1,001-5,000 employees

Corporate venture capital for deep-tech startups

Compensation Overview

CA$77k - CA$110k/yr

+ Commission + Performance bonus

Montreal, QC, Canada + 2 more

More locations: Toronto, ON, Canada | Vancouver, BC, Canada

Hybrid

Primarily home-office based, with approximately 75% of time spent on-site at customer locations. Domestic and overseas travel is required.

Master's, PhD

Category
Sales & Account Management (1)
Biology & Biotech (1)
Required Skills
Microsoft Office
Sales
CRM
Salesforce

Get referred to Zeiss

See people who can refer or advise you

Requirements
  • A Master's or Ph.D. in Life Sciences, Biotechnology, Pharmaceutical Sciences, Engineering, or a related field is required.
  • At least 3–5 years of experience in account management, sales, or business development within the biotech, pharmaceutical, or industrial sectors is required.
  • A proven track record selling high-value laboratory instrumentation is required.
  • Working knowledge of advanced microscopy, specifically Laser Scanning Confocal Microscopy and Super-Resolution techniques, is required.
  • Understanding of automated time-lapse, Z-stacking, and tiling, with practical applications in industrial research and development or quality assurance and quality control environments, is required.
  • Knowledge and experience in biological applications and end-to-end workflow solutions are required.
  • Proven success managing and growing key accounts within a technical or scientific field is required.
  • Strong proficiency in Microsoft Office, customer relationship management platforms such as Salesforce, and virtual presentation tools is required.
  • The candidate must be legally eligible to work in Canada and provide valid documentation upon request.
  • The candidate must hold a valid passport and be legally eligible for international business travel to the United States and European Union.
  • The candidate must maintain a high awareness of laboratory risks and uphold personal safety standards when visiting client institutions.
Responsibilities
  • Identify, prospect, and qualify new business opportunities within biotech, pharmaceutical, pre-clinical, contract research organization, and research and development sectors through outbound outreach, networking, and industry research.
  • Conduct discovery sessions to uncover prospect pain points and deliver tailored presentations demonstrating return on investment for high-content screening, drug discovery, 3D cellular imaging, and super-resolution microscopy.
  • Deliver technical presentations to key opinion leaders, laboratory managers, and procurement heads on solutions, services, and capabilities focused on how automated microscopy reduces time to market.
  • Monitor industry trends and competitor activity to identify emerging market segments and refine the value proposition for the contract research organization market, focusing on data reproducibility and multi-site scalability.
  • Lead the end-to-end sales cycle for capital equipment and microscopy-as-a-service solutions, including request-for-purchase responses and complex contract negotiations.
  • Use the ZEISS Sales Process and Challenger Sales techniques to qualify opportunities and challenge the status quo.
  • Own the information-gathering phase by assessing customer needs, budgets, and timelines across the product, application, and functionality portfolio.
  • Maintain responsibility for sales while leading by influence and collaborating with Product and Applications Sales Specialists on complex system sales.
  • Drive the sales motion from lead response through information sharing and final closure using in-lab and remote presentation platforms.
  • Serve as the primary technical and commercial liaison for established accounts, ensuring imaging systems remain optimized for regulatory-compliant workflows such as good manufacturing practice and good laboratory practice.
  • Respond to new leads within 24 hours and convert or disqualify all customer relationship management data within seven days.
  • Maintain customer relationship management data hygiene so the sales funnel remains current and forecasting is accurate for the Head of Sales.
  • Build high-touch relationships through face-to-face interaction with end users, procurement personnel, supervisors, and key decision influencers.
  • Generate technically accurate quotes and proposals aligned with customer application demands while maximizing value.
  • Partner with Sales Support and Logistics to streamline order booking and system delivery.
  • Coordinate with Service stakeholders to manage successful system installations and secure the Customer Acceptance Certificate before training.
  • Complete the Customer Perfect Order form within 30 days of qualifying orders.
  • Care for demonstration equipment and execute return procedures on time.
  • Engage in personal development through the CurioZ online training portal and independent learning to remain knowledgeable about advanced microscopy solutions.
Desired Qualifications
  • Expertise in image analysis, bioinformatics, and artificial intelligence-driven data quantification.
  • Prior experience managing a field coverage area for technical sales or product support.
  • Knowledge of laboratory safety requirements for Biosafety Level 3 and safe handling of Level 3 pathogenic biohazards.
  • Willingness to engage customers directly within Biosafety Level 2 and Biosafety Level 3 facilities.
  • Willingness and ability to travel domestically and overseas, including international trade shows, corporate meetings, and global project teams.
  • Ability to lift and maneuver equipment crates weighing approximately 75 pounds for system transport and setup.
  • A driving record in good standing and a valid Canadian driver's license for operating a company-provided car or van.
  • Ability to present professionally and effectively in person and from a remote home-office environment.

ZEISS Ventures is the corporate venture capital arm of the ZEISS Group, investing in deep-tech startups in Information Technology, Industrial Tech, MedTech, and Life Sciences. It backs early-stage companies at pre-Series A to Series A with typical investments of $1–5 million. The fund provides capital and tailored funding solutions, leveraging ZEISS’s global network and optics/optoelectronics expertise to support portfolio companies. Its goal is to accelerate the development of new technologies and business models that complement ZEISS’s portfolio while actively engaging with external innovation.

Company Size

1,001-5,000

Company Stage

Growth Equity (Non-Venture Capital)

Total Funding

$67.7M

Headquarters

Oberkochen, Germany

Founded

2001

Get referred to Zeiss

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • ZEISS led Maculaser's May 2026 round for retinal laser therapy commercialization.
  • ZEISS Ventures led SeeTrue's €2.2 million round on August 6, 2026.
  • ZEISS launched ClearMind lenses and DuraVision Plus in January 2026, reinforcing optical leadership.

What critics are saying

  • Carl Zeiss Meditec cut 2026 revenue 5.7% and targets 1,000 job reductions.
  • ZEISS's 2026 restructuring threatens innovation velocity and employee morale through 2028/29.
  • A prolonged MedTech slump or failed turnaround would weaken ZEISS Ventures' strategic value.

What makes Zeiss unique

  • ZEISS Ventures pairs capital with ZEISS distribution, engineering, and ophthalmology channels.
  • Its 2026 deals target eye health, imaging, and optoelectronics adjacencies.
  • ZEISS brand credibility de-risks pilots for startups selling into regulated healthcare.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

Paid Vacation

Performance Bonus

Company News

PR Newswire
Aug 19th, 2026
ZEISS CLINIC 360 receives FDA clearance for cloud-based ophthalmic data management software

ZEISS Medical Technology announced FDA 510(k) clearance for ZEISS CLINIC 360, a cloud-based software solution that aggregates ophthalmic clinical data and provides advanced analytics. The browser-based platform combines diagnostic and medical data into a comprehensive patient view, helping clinicians evaluate disease progression and support treatment decisions. The solution integrates data from DICOM-enabled diagnostic devices, including ZEISS's CIRRUS, CLARUS and HFA systems, as well as third-party devices. It features disease-based summaries, interactive analysis tools, and collaboration capabilities through ZEISS Collaborative Care. ZEISS CLINIC 360 will be available in the US in early autumn 2026 on a subscription basis with low upfront costs. The platform complements ZEISS FORUM, the company's on-premise data management system, giving providers flexibility in choosing their preferred infrastructure approach.

ZEISS
Aug 5th, 2026
ZEISS leads $2.5M investment in SeeTrue Technologies for miniaturised eye-tracking tech

ZEISS Ventures led a €2.2 million investment round in SeeTrue Technologies, a Finnish deep-tech company developing miniaturised eye-tracking technology. The funding will accelerate commercialisation of SeeTrue's ultra-low-power eye-sensing architecture for next-generation interfaces in smart optical systems and eyewear. SeeTrue's proprietary technology combines miniaturised sensing hardware with optimised embedded processing, enabling scalable eye-sensing capabilities with low power consumption and small hardware footprint. The technology supports gaze-based interaction and attention-aware computing across healthcare, industrial, and smart eyewear applications. The investment round includes participation from Superhero Capital and North Karelia Growth Fund, managed by Redstone Nordics. Founded in 2018 and based in Joensuu, Finland, SeeTrue develops ultra-miniature eye-tracking technology for medical optical systems, vision care, and smart wearables.

PR Newswire
Jun 11th, 2026
ZEISS completes early implantations of AT LUCIA toric 721P intraocular lens

ZEISS Medical Technology has announced successful early clinical implantations of its AT LUCIA toric 721P intraocular lens, designed to treat cataracts whilst correcting astigmatism. The company is conducting an early-access clinical trial with experienced surgeons across six European countries. The lens combines an aspheric bitoric optic with a patented non-constant aberration design on a fully preloaded, hydrophobic platform. Surgeons have reported positive early impressions, highlighting the lens's precision, stability and surgical handling. Currently CE marked, the AT LUCIA toric 721P will be showcased at the International Congress of German Ophthalmic Surgery in Nuremberg from 18–20 June 2026. The lens is expected to be commercially available in select European countries later this year.

ZEISS
May 28th, 2026
ZEISS invests in Maculaser to advance temperature-controlled retinal laser therapy

ZEISS Ventures has invested in Maculaser, a Finnish medtech company developing temperature-controlled retinal laser therapy, through a funding round co-led with M2care. The investment will support clinical development of the company's personalized treatment for retinal diseases. Founded in 2020 and based on research from Aalto University, Maculaser has developed patented technology that provides real-time temperature control during laser treatment. The non-damaging approach activates natural cellular defence mechanisms, targeting affected retinal areas early to delay or prevent progression of age-related macular degeneration and diabetic maculopathy. The technology aims to shift retinal care from managing late-stage damage to proactive vision preservation, offering an outpatient procedure that integrates into regular eye care. Maculaser plans to bring the treatment into clinical practice to benefit millions of patients worldwide.

PR Newswire
May 13th, 2026
ZEISS gains COFEPRIS approval for ARTEVO 850 and MICOR 700 ophthalmic surgical systems in Mexico

ZEISS Medical Technology has received approval from Mexico's COFEPRIS for two ophthalmic surgical devices: the ARTEVO 850 microscope and MICOR 700 lens removal device. Both technologies are compatible with ZEISS's latest cataract workflow systems. The ARTEVO 850 is a 3D heads-up ophthalmic microscope offering true colour imaging and a nearly 60% increase in depth of field. The MICOR 700 is the first handheld lens removal device with ultrasound-free operation, using ZEISS's non-ultrasonic lens extraction procedure to minimise risk to surrounding eye structures. The products will be showcased at the Mexican Congress of Ophthalmology in Monterrey from 30 May to 3 June 2026. ZEISS Medical Technology generated revenue of €2,066.1 million in fiscal year 2023/24.